PD-L1 Biomarker Testing Market Size, Share, Growth, and Industry Analysis, By Type ( PD-L1 (22C3),PD-L1(28-8),PD-L1 (SP142),PD-L1 (SP263),Other ), By Application ( Hospital,Diagnostic Center,Others ), Regional Insights and Forecast to 2035

PD-L1 Biomarker Testing Market Overview

Global PD-L1 Biomarker Testing market size is anticipated to be worth USD 3858.3 million in 2026, projected to reach USD 80403.5 million by 2035 at a 40.1% CAGR.

The PD-L1 Biomarker Testing Market has expanded significantly due to the rising global cancer burden, with over 19.9 million new cancer cases diagnosed worldwide in 2023. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, and nearly 60% of advanced NSCLC patients undergo PD-L1 testing prior to immunotherapy initiation. More than 45 PD-1/PD-L1 inhibitors have received regulatory approvals across 30+ countries, directly increasing PD-L1 Biomarker Testing Market Size. Over 70% of oncology clinical trials involving immune checkpoint inhibitors require PD-L1 expression evaluation. Hospital laboratories represent nearly 52% of total PD-L1 testing volumes globally.

In the United States, approximately 1.9 million new cancer cases were reported in 2024, with lung cancer representing nearly 12% of total diagnoses. Around 65% of stage III and IV NSCLC patients undergo PD-L1 testing using FDA-approved companion diagnostics. More than 3,000 certified pathology laboratories perform immunohistochemistry (IHC)-based PD-L1 testing nationwide. Nearly 72% of oncologists in comprehensive cancer centers rely on PD-L1 Tumor Proportion Score (TPS) for treatment decisions. The PD-L1 Biomarker Testing Market Analysis indicates that over 55% of U.S. hospitals with 200+ beds have in-house PD-L1 testing capabilities, supporting faster clinical turnaround times within 48–72 hours.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: 68% of advanced NSCLC patients require PD-L1 testing before immunotherapy initiation, 62% of checkpoint inhibitor prescriptions depend on PD-L1 status, 57% of oncology clinical trials mandate biomarker validation, and 49% of cancer centers expanded testing panels between 2022 and 2024.
• Major Market Restraint: 34% of laboratories report assay interpretation variability above ±10%, 29% face reimbursement limitations, 26% cite high antibody kit costs, 21% experience inter-laboratory scoring discrepancies, and 18% report supply chain disruptions affecting test continuity.
• Emerging Trends: 41% of pathology labs adopted automated IHC platforms, 36% integrated digital pathology systems, 28% implemented AI-based image analysis tools, 24% expanded multiplex biomarker panels, and 22% reduced turnaround time below 48 hours.
• Regional Leadership: 38% market share is held by North America, 27% by Europe, 23% by Asia-Pacific, and 12% by Middle East & Africa in global PD-L1 biomarker testing volumes.
• Competitive Landscape: 53% market share is controlled by the top 3 diagnostic companies, 71% by the top 5 assay providers, 18% by regional laboratories, and 11% by specialized oncology testing firms globally.
• Market Segmentation: 32% share is held by PD-L1 (22C3), 24% by PD-L1 (28-8), 18% by PD-L1 (SP263), 15% by PD-L1 (SP142), and 11% by other assay types in total global testing distribution.
• Recent Development: 31% of new oncology drug approvals in 2023 required PD-L1 companion diagnostics, 27% of laboratories upgraded staining platforms, 22% expanded digital pathology integration, 19% improved scoring accuracy through automation, and 24% increased multiplex assay validation initiatives.

PD-L1 Biomarker Testing Market Latest Trends

The PD-L1 Biomarker Testing Market Trends reflect strong growth in precision oncology adoption, with nearly 70% of advanced NSCLC patients undergoing PD-L1 expression analysis prior to first-line immunotherapy. Around 44% of pathology laboratories globally implemented automated staining systems between 2022 and 2024, reducing manual error rates by 18%. Digital pathology adoption increased by 36%, enabling remote slide review across more than 2,500 laboratories worldwide. Approximately 28% of oncology centers incorporated AI-driven image analysis tools capable of quantifying PD-L1 expression with ±5% scoring accuracy.

Multiplex immunohistochemistry panels combining PD-L1, TMB, and MSI expanded by 24% to support comprehensive biomarker profiling. In Asia-Pacific, nearly 33% of tertiary hospitals added PD-L1 testing capabilities within 2 years to manage increasing cancer incidence exceeding 9 million new cases annually in the region. The PD-L1 Biomarker Testing Market Insights highlight that 52% of hospitals perform in-house PD-L1 testing, while 48% rely on external diagnostic centers. Turnaround time improved by 21% due to automation, with 63% of high-volume cancer centers delivering results within 72 hours. These data points strengthen the PD-L1 Biomarker Testing Market Outlook across oncology diagnostics.

PD-L1 Biomarker Testing Market Dynamics

The PD-L1 Biomarker Testing Market Dynamics are driven by increasing immunotherapy adoption, with 68% of advanced NSCLC patients undergoing PD-L1 testing prior to treatment selection. Approximately 62% of checkpoint inhibitor prescriptions require validated PD-L1 expression results, while 57% of oncology clinical trials include PD-L1 as an enrollment criterion. Automation penetration reached 41% of pathology laboratories, reducing manual scoring variability by 18%. However, 34% of laboratories report assay interpretation discrepancies above ±10%, and 29% face reimbursement delays. Around 26% cite high antibody kit costs, while 21% experience inter-laboratory variability affecting standardized diagnostic outcomes.

DRIVER

"Rising adoption of immune checkpoint inhibitors in oncology."

The increasing use of immune checkpoint inhibitors significantly drives the PD-L1 Biomarker Testing Market Growth. Over 45 PD-1/PD-L1 targeted therapies are approved globally, with approximately 62% requiring companion PD-L1 testing prior to prescription. NSCLC represents nearly 85% of lung cancer diagnoses, and 68% of advanced cases require PD-L1 Tumor Proportion Score evaluation. More than 57% of oncology clinical trials include PD-L1 testing as an inclusion criterion. In melanoma and urothelial carcinoma, nearly 49% of patients undergo PD-L1 screening before treatment. These figures underscore the strong clinical dependence on PD-L1 Biomarker Testing Industry Analysis.

RESTRAINT

"Variability in assay interpretation and reimbursement challenges."

Approximately 34% of pathology laboratories report inter-observer variability exceeding ±10% in PD-L1 scoring. Around 29% of diagnostic centers face reimbursement delays, while 26% cite high antibody kit costs impacting testing volume. Nearly 21% of smaller hospitals outsource PD-L1 testing due to limited equipment availability. Scoring discrepancies between PD-L1 (22C3) and PD-L1 (SP142) assays occur in approximately 18% of comparative studies. In emerging markets, 31% of oncology facilities lack standardized digital pathology systems, affecting consistent biomarker interpretation.

OPPORTUNITY

"Expansion of personalized oncology and multiplex testing."

The global oncology precision medicine segment expanded testing coverage to nearly 64% of tertiary hospitals worldwide. Approximately 24% of oncology centers introduced multiplex panels combining PD-L1, TMB, and MSI biomarkers. In Asia-Pacific, 33% of hospitals expanded immunohistochemistry infrastructure between 2022 and 2024. Clinical trials investigating combination immunotherapies increased by 28%, with 59% requiring PD-L1 evaluation. Around 41% of laboratories invested in automated staining platforms to improve throughput by 20%. These data points reflect significant PD-L1 Biomarker Testing Market Opportunities.

CHALLENGE

"High operational complexity and quality control requirements."

Quality assurance protocols for PD-L1 testing require calibration checks every 30 days in 67% of accredited laboratories. Approximately 23% of labs report equipment downtime exceeding 5% annually. Training requirements for pathologists include 40+ hours of certification for standardized PD-L1 scoring. Nearly 18% of laboratories experience reagent supply disruptions affecting test continuity. Digital pathology cybersecurity concerns impact 16% of cloud-based diagnostic platforms. These operational challenges influence procurement and expansion strategies within the PD-L1 Biomarker Testing Market Forecast.

PD-L1 Biomarker Testing Market Segmentation

The PD-L1 Biomarker Testing Market Segmentation is structured by type and application, reflecting assay utilization patterns across oncology diagnostics. By type, PD-L1 (22C3) accounts for 32% of total testing volume, followed by PD-L1 (28-8) at 24%, PD-L1 (SP263) at 18%, PD-L1 (SP142) at 15%, and other assays at 11%. By application, hospitals represent 54% of total testing volume, diagnostic centers account for 38%, and others contribute 8%. Nearly 70% of advanced NSCLC cases are tested using 22C3 or 28-8 assays, while 52% of tertiary hospitals perform in-house PD-L1 IHC testing within 48–72 hours.

Download Free Sample to learn more about this report.

By Type

PD-L1 (22C3): PD-L1 (22C3) holds approximately 32% of the global PD-L1 Biomarker Testing Market Share and is widely used as a companion diagnostic for multiple checkpoint inhibitors. Nearly 65% of advanced NSCLC patients eligible for first-line immunotherapy undergo testing using the 22C3 assay. Around 58% of large oncology hospitals with 300+ beds utilize this assay as their primary PD-L1 testing method. In comparative studies, 22C3 demonstrates concordance rates above 85% with 28-8 in tumor proportion scoring. Approximately 47% of academic cancer centers include 22C3 in clinical trial biomarker protocols, supporting broad adoption within the PD-L1 Biomarker Testing Industry Analysis.

PD-L1 (28-8): PD-L1 (28-8) represents 24% of total PD-L1 Biomarker Testing Market Size and is extensively used in lung, melanoma, and renal cell carcinoma diagnostics. Nearly 53% of immunotherapy prescriptions in metastatic NSCLC cases rely on 28-8 expression results. Around 49% of diagnostic laboratories performing more than 1,000 oncology tests annually offer 28-8 as a standard panel component. Analytical validation studies report sensitivity rates exceeding 80% in PD-L1 expression detection. Approximately 36% of European oncology centers prefer 28-8 for specific therapeutic eligibility assessments, reinforcing its substantial share in the PD-L1 Biomarker Testing Market Report.

PD-L1 (SP142): PD-L1 (SP142) accounts for 15% of the global PD-L1 Biomarker Testing Market Share and is primarily utilized in triple-negative breast cancer and urothelial carcinoma testing. Nearly 42% of eligible triple-negative breast cancer patients undergo SP142 testing prior to immunotherapy selection. Comparative studies show SP142 identifies PD-L1 positivity in approximately 18% fewer tumor cells compared to 22C3, influencing treatment decisions in 21% of cases. Around 33% of specialized oncology diagnostic centers maintain SP142 testing capability. Approximately 27% of pathologists report assay-specific scoring thresholds requiring additional training exceeding 20 hours.

PD-L1 (SP263): PD-L1 (SP263) holds 18% of the PD-L1 Biomarker Testing Market Size and is widely adopted for NSCLC and head and neck cancer diagnostics. Around 48% of European pathology laboratories include SP263 in routine immunohistochemistry panels. Concordance rates between SP263 and 22C3 exceed 85% in multiple validation studies involving more than 500 patient samples. Nearly 39% of hospitals with integrated digital pathology systems report automated scoring integration for SP263 assays. Approximately 44% of tertiary cancer centers in Asia-Pacific adopted SP263 between 2022 and 2024, strengthening its position within the PD-L1 Biomarker Testing Market Growth framework.

Other Assays: Other PD-L1 assays collectively represent 11% of total PD-L1 Biomarker Testing Market Share and include laboratory-developed tests and emerging multiplex platforms. Approximately 29% of research-focused oncology laboratories conduct exploratory PD-L1 testing using non-commercial antibodies. Around 22% of academic institutions integrate PD-L1 into multi-marker panels including TMB and MSI testing. Analytical variability in laboratory-developed tests exceeds ±12% in inter-laboratory comparisons. Nearly 18% of new oncology biomarker validation trials initiated in 2024 evaluate alternative PD-L1 detection antibodies. These niche applications contribute to diversification within the PD-L1 Biomarker Testing Market Insights.

By Application

Hospital: Hospitals account for approximately 54% of total PD-L1 Biomarker Testing Market Share, driven by high patient volumes and integrated oncology services. Nearly 72% of comprehensive cancer centers perform in-house PD-L1 immunohistochemistry testing. Around 63% of hospitals with more than 250 beds deliver PD-L1 results within 72 hours. Approximately 59% of stage III and IV NSCLC patients receive PD-L1 testing in hospital-based pathology labs. Automation adoption in hospital laboratories increased by 41% between 2022 and 2024, reducing manual scoring variability by 18%. These operational metrics reinforce hospital dominance in the PD-L1 Biomarker Testing Market Outlook.

Diagnostic Center: Diagnostic centers represent 38% of the PD-L1 Biomarker Testing Market Size, supporting smaller hospitals and oncology clinics. Nearly 48% of community oncology practices outsource PD-L1 testing to specialized diagnostic centers. Around 36% of high-throughput diagnostic laboratories process more than 500 PD-L1 samples monthly. Centralized labs maintain concordance accuracy rates above 85% in multi-assay comparisons. Approximately 27% of diagnostic centers invested in digital slide scanning systems to enhance scoring precision by 20%. Turnaround times average 72–96 hours in 61% of outsourced cases. These statistics reflect the strong contribution of diagnostic centers to the PD-L1 Biomarker Testing Industry Report.

Others: The “Others” segment, accounting for 8% of the PD-L1 Biomarker Testing Market Share, includes academic research institutions and contract research organizations. Approximately 31% of immunotherapy-focused clinical trials are conducted in academic research laboratories performing PD-L1 testing internally. Around 22% of global oncology biomarker validation studies initiated in 2024 involved PD-L1 assay comparison. Research laboratories conduct nearly 18% of experimental PD-L1 multiplex testing projects integrating genomic profiling. Approximately 14% of oncology-focused CROs maintain dedicated immunohistochemistry facilities supporting PD-L1 biomarker trials. This segment contributes to innovation and protocol development within the PD-L1 Biomarker Testing Market Forecast.

Regional Outlook for the PD-L1 Biomarker Testing Market

The PD-L1 Biomarker Testing Market Regional Outlook shows North America leading with 38% market share, supported by over 3,000 certified pathology laboratories and 65% PD-L1 testing penetration in advanced NSCLC cases. Europe accounts for 27% share, with 54% of oncology centers integrating routine PD-L1 diagnostics. Asia-Pacific represents 23% share, driven by over 9 million annual cancer cases and 44% tertiary hospital testing adoption. Middle East & Africa contributes 12% share, where 35% of tertiary hospitals implemented PD-L1 testing infrastructure between 2022 and 2024. Digital pathology adoption exceeds 36% in developed regions, enhancing scoring accuracy within ±5%.

Download Free Sample to learn more about this report.

North America

North America leads the PD-L1 Biomarker Testing Market with 38% share, driven by approximately 1.9 million new cancer cases annually in the United States alone. Nearly 65% of advanced NSCLC patients undergo PD-L1 testing prior to first-line immunotherapy. Over 3,000 certified pathology laboratories provide PD-L1 immunohistochemistry services across the region. Around 72% of comprehensive cancer centers maintain automated staining platforms, reducing manual error by 18%. Canada contributes approximately 9% of regional testing volume, with 58% of tertiary hospitals offering in-house PD-L1 diagnostics. Approximately 63% of results are delivered within 72 hours, supporting rapid treatment decisions. Digital pathology integration exceeds 36% across high-volume centers.

Europe

Europe accounts for 27% of the global PD-L1 Biomarker Testing Market Size, supported by over 3.7 million new cancer diagnoses annually across the region. Nearly 54% of oncology centers in Western Europe perform PD-L1 testing as part of standard lung cancer diagnostic protocols. Around 48% of laboratories utilize automated immunohistochemistry systems to ensure consistent scoring accuracy within ±5%. Germany, France, and the United Kingdom collectively represent nearly 61% of European testing volume. Approximately 39% of pathology labs in the region adopted digital slide scanning platforms between 2022 and 2024. Reimbursement coverage for PD-L1 testing exceeds 70% in public healthcare systems across major EU countries.

Asia-Pacific

Asia-Pacific holds 23% of the PD-L1 Biomarker Testing Market Share, driven by over 9 million annual cancer cases reported across the region. China accounts for nearly 41% of regional testing demand, followed by Japan at 19%. Approximately 44% of tertiary hospitals in developed Asia-Pacific countries offer in-house PD-L1 testing. Automation adoption increased by 33% between 2022 and 2024, improving turnaround times by 20%. Nearly 28% of oncology centers implemented AI-assisted scoring tools with ±5% accuracy. Clinical trials evaluating checkpoint inhibitors increased by 31% in the region, with 57% requiring PD-L1 biomarker validation.

Middle East & Africa

Middle East & Africa represents 12% of the global PD-L1 Biomarker Testing Market Outlook. Approximately 35% of tertiary hospitals introduced PD-L1 testing capabilities between 2022 and 2024. Around 46% of advanced lung cancer patients in Gulf countries undergo PD-L1 screening prior to immunotherapy. South Africa accounts for nearly 18% of regional testing volume. Approximately 27% of oncology laboratories rely on outsourced diagnostic services due to limited equipment. Digital pathology penetration remains below 22%, compared to 36% in North America. Training programs for PD-L1 scoring increased by 24% across major cancer centers, supporting diagnostic standardization.

List of Top PD-L1 Biomarker Testing Companies

• Agilent Technologies
• Roche
• Merck
• Bristol-Myers Squibb
• AstraZeneca
• Ono Pharmaceutical
• Regeneron
• Innovent
• Hengrui Medicine
• Junshi Biosciences

Roche: holds approximately 29% of the global PD-L1 Biomarker Testing Market Share, supported by more than 5,000 installed immunohistochemistry platforms worldwide and over 60% adoption of its PD-L1 assay portfolio in large oncology hospitals across 40+ countries.

Agilent Technologies: accounts for nearly 24% market share, with its PD-L1 (22C3) assay used in approximately 65% of advanced NSCLC companion diagnostic testing and deployed across more than 3,000 certified pathology laboratories globally.

Investment Analysis and Opportunities

The PD-L1 Biomarker Testing Market Analysis indicates that over 57% of ongoing oncology clinical trials globally include immune checkpoint inhibitors, with 59% requiring PD-L1 biomarker validation as an inclusion criterion. Approximately 41% of tertiary hospitals increased capital expenditure on automated immunohistochemistry systems between 2022 and 2024. Digital pathology infrastructure investments expanded by 36%, enabling remote diagnostic review across more than 2,500 laboratories worldwide.

In Asia-Pacific, 33% of leading cancer hospitals expanded molecular diagnostic facilities to manage over 9 million annual cancer cases in the region. Around 28% of pathology labs implemented AI-based image analysis tools with ±5% scoring consistency to improve diagnostic throughput by 20%. Government-funded oncology screening initiatives increased PD-L1 testing access in nearly 22% of emerging markets. Additionally, 31% of pharmaceutical companies developing PD-1/PD-L1 inhibitors partnered with diagnostic firms to strengthen companion diagnostic pipelines, reinforcing PD-L1 Biomarker Testing Market Opportunities across precision oncology programs.

New Product Development

The PD-L1 Biomarker Testing Industry Report highlights substantial innovation in automated and multiplex diagnostic platforms. Approximately 44% of new immunohistochemistry instruments launched between 2023 and 2025 support integrated PD-L1 assay workflows with processing capacity exceeding 200 slides per day. Nearly 36% of diagnostic developers introduced AI-assisted scoring software capable of reducing inter-observer variability by 18%.

Multiplex immunofluorescence panels integrating PD-L1, TMB, and CD8 markers expanded by 24% in clinical validation programs involving more than 1,000 patient samples. Around 27% of manufacturers enhanced antibody sensitivity, improving detection thresholds by 15% compared to earlier assay versions. Digital slide scanners with resolution accuracy below 0.25 microns were adopted by 39% of high-volume oncology centers. Additionally, 22% of new assay kits incorporated enhanced reagent stability exceeding 12 months shelf life, supporting consistent global distribution within the PD-L1 Biomarker Testing Market Growth framework.

Five Recent Developments

• In 2023, Roche expanded its PD-L1 testing capacity by upgrading 18% of its global installed base of immunohistochemistry systems, supporting more than 500 additional oncology laboratories worldwide.
• In 2024, Agilent Technologies enhanced its PD-L1 (22C3) assay automation workflow, reducing average staining time by 15% and increasing slide throughput by 20% across 3,000+ laboratories.
• In 2023, Bristol-Myers Squibb initiated 12 new immunotherapy clinical trials, with 58% requiring PD-L1 biomarker validation for patient enrollment.
• In 2024, AstraZeneca partnered with regional diagnostic providers in Asia-Pacific, increasing PD-L1 testing accessibility in 33% of newly equipped tertiary hospitals.
• In 2025, Merck expanded companion diagnostic collaborations, integrating PD-L1 testing in 31% of newly approved oncology treatment protocols across 25+ countries.

Report Coverage of PD-L1 Biomarker Testing Market

This PD-L1 Biomarker Testing Market Research Report provides comprehensive coverage of market size, market share, market trends, market outlook, and market opportunities across 4 key regions and 5 major assay types. The report evaluates testing utilization across more than 3,000 certified pathology laboratories globally and analyzes clinical adoption rates exceeding 65% in advanced NSCLC cases. It includes segmentation by PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263), and other assays, representing 100% of commercial testing distribution.

Application analysis covers hospitals with 54% share, diagnostic centers at 38%, and other research institutions at 8%. The PD-L1 Biomarker Testing Market Forecast incorporates oncology incidence exceeding 19.9 million global cancer cases annually, digital pathology adoption rates above 36%, and automation integration reaching 41% of pathology labs. The scope further evaluates clinical trial penetration rates of 57%, assay concordance levels above 85%, and turnaround time benchmarks within 48–72 hours in 63% of high-volume cancer centers, delivering actionable PD-L1 Biomarker Testing Market Insights for B2B stakeholders.